Benefits of Danazol Treatment in Patients With Hemophilia A (Classic Hemophilia)

Harvey R. Gralnick
In: JAMA: The Journal of the American Medical Association · 1985 · vol. 253(8) , pp. 1151 · doi:10.1001/jama.1985.03350320075020 · PMID:3918188 · W1978614772
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

Danazol, an attenuated androgen, was given intermittently in three patients with hemophilia A. The rise in factor VIII activity with danazol treatment was associated with a fivefold decrease in hemorrhagic episodes and plasma concentrate product utilization when compared with similar periods without the drug. Four other patients with moderate hemophilia A who received danazol for 14 days had an increase of 400% to 850% in their factor VIII levels. Of four patients without detectable levels of factor VIII who were treated with danazol, two had elevations of the factor VIII level, to 3% and 4%, respectively. Danazol appears to be an effective treatment for patients with hemophilia A.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (9)

Cited by (5)

Source provenance

openalex
last seen: 2026-05-10T10:36:00.256005+00:00
License: CC0 · commercial use OK